Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones

被引:11
作者
Blondeau, J. M.
Blondeau, L. D.
Hesje, C.
Borsos, S.
机构
[1] Royal Univ Hosp, Dept Clin Microbiol, Saskatoon, SK S7N 0W8, Canada
[2] Univ Saskatchewan, Dept Microbiol & Immunol, Saskatoon Hlth Reg, Saskatoon, SK S7N 0W0, Canada
[3] Univ Saskatchewan, Dept Pathol, Saskatoon Hlth Reg, Saskatoon, SK S7N 0W0, Canada
关键词
Streptococcus pneumoniae; killing activity; gemifloxacin; moxifloxacin; levofloxacin; gatifloxacin;
D O I
10.1179/joc.2006.18.4.366
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Minimum inhibitory concentration (MIC) testing measures the lowest drug concentration that prevents microbial growth using an inocullum of 105 colony forming units/ml (cfu/ml) whereas the mutant prevention concentration (MPC) (inocullum approximate to 10(10) cells) defines the antimicrobial drug concentration threshold that would require an organism to possess two simultaneous mutations for continued growth in the presence of the drug. The rates at which multidrug-resistant Streptococcus pneumoniae [MDRSP] were killed by the respiratory fluoroquinolones, gatifloxacin, gemfloxacin, levofloxacin and moxifloxacin, were compared based on the MIC and MPC drug concentrations and at inocula ranging from 10(6)-10(9) cfu/ml. The MIC drug concentration failed to eradicate all viable cells whereas the MPC drug concentration resulted in 99.9% to 100% cellular reduction following 12-24 hours of drug exposure. MPC values against S. pneumoniae were different for each fluoroquinolone. The MPC drug concentration prevents the selection of multidrug-resistant or fluoroquinolone-resistant S. pneumoniae. The value of dosing of antimicrobial agents based on MPC thresholds results in a rapid reduction in viable cells - even at higher inocula which are more reflective of organism burden in pneumonia. The rapid reduction in viable cells observed at MPC drug concentrations may not only have an impact on preventing the selection of resistant mutants but may also help explain the rapid symptom resolution seen with new fluoroquinolones since these agents lead to little or low release of cell contents which are known to drive the inflammatory response.
引用
收藏
页码:366 / 372
页数:7
相关论文
共 24 条
[1]  
Blondeau J M, 2004, J Chemother, V16 Suppl 3, P1
[2]   Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae [J].
Blondeau, JM ;
Zhao, XL ;
Hansen, G ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :433-438
[3]   A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones' [J].
Blondeau, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :1-11
[4]  
Blondeau JM, 2002, ROY S MED S, P15
[5]  
BLONDEAU JM, 2005, THERAPY, V2, P511
[6]   Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].
Chen, DK ;
McGeer, A ;
de Azavedo, JC ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239
[7]  
*CLIN LAB STAND I, 2005, PERFORMANCE STANDARD, V24
[8]  
Clinical and Laboratory Standards Institute, 2006, METH DIL ANT SUSC TE
[9]   Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy [J].
Dagan, R ;
Klugman, KP ;
Craig, WA ;
Baquero, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (02) :129-140
[10]   Brief report: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. [J].
Davidson, R ;
Cavalcanti, R ;
Brunton, JL ;
Bast, DJ ;
de Azavedo, JCS ;
Kibsey, P ;
Fleming, C ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (10) :747-750